REFERENCES
1. Chen Y, Chen D, Liang Z, et al. Immune checkpoint inhibitors in hepatocellular carcinoma therapy: resistance mechanisms, liver transplantation challenges and management strategies. Cancer Drug Resist. 2025;8:48.
2. Qi D, Qin Y, Zhu H, Li Y, Han S. Resistance of first-line targeted drugs in hepatocellular carcinoma: the epigenetic regulation mechanisms. Cell Death Dis. 2025;16:875.
3. Sun Y, Luo C, Yang H, et al. Lactylation converts ABHD6 into a mitochondrial regulator that drives lenvatinib resistance in hepatocellular carcinoma. Cancer Res. 2026;86:2970-89.
4. Zhang Y, Lin Y, Cai H, Zhou T. EZH2 confers lenvatinib resistance in hepatocellular carcinoma by suppressing ACSL1-Mediated ferroptosis. BMC Cancer. 2025;25:1638.
5. Xu, M. , Zheng, Y., Zhao, L., et al. Activation of nerve growth factor signaling limits the response to lenvatinib in hepatocellular carcinoma. Signal Transduct Target Ther. 2026;11:10.
6. Ferraguti G, Terracina S, Tarani L, et al. Nerve growth factor and the role of inflammation in tumor development. Curr Issues Mol Biol. 2024;46:965-89.
7. Yin T, Wang G, Wang L, et al. Breaking NGF-TrkA immunosuppression in melanoma sensitizes immunotherapy for durable memory T cell protection. Nat Immunol. 2024;25:268-81.
8. Balasubramanian K, Fung KM, McNall-Knapp RY, Balsara K. Sustained response to larotrectinib in a pediatric patient with recurrent STRN3::NTRK2 fusion-positive pilocytic astrocytoma. CNS Oncol. 2025;14:2558455.
9. Yamazaki H, Sugimori M, Saito A. Larotrectinib efficacy for liver metastases in papillary thyroid carcinoma patient harboring SQSTM1-NTRK1 fusion. Surg Case Rep. 2024;10:171.
